Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. PSC can be divided into five subtypes based on the 2015 World Health Organization (WHO) classification of lung tumors: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. Some imaging characteristics can be found for PSC although no special symptoms. The accurate pathological diagnosis of PSC can be a significant challenge, which depends on pathology and immunohistochemistry. PSC should be managed similar to other NSCLC, surgical resection is the standard management for early stage cases, moreover, multimodal treatment should be considered. However, PSC is insensitive to radiotherapy and chemotherapy, and has high rate of local and metastatic recurrence and poor prognosis. With the development of molecular pathology, targeted therapy and immunotherapy may have broad prospects. .
【中文题目：肺肉瘤样癌的诊治现状】 【中文摘要：肺肉瘤样癌（pulmonary sarcomatoid carcinoma, PSC）是一类罕见的非小细胞肺癌的统称，约占肺恶性肿瘤的0.1%-0.5%，按照2015年世界卫生组织（World Health Organization, WHO）对于肺恶性肿瘤分类标准，属于肺恶性上皮细胞肿瘤，包含5个亚型：多形性癌、梭形细胞癌、巨细胞癌、癌肉瘤和肺母细胞瘤。该类疾病无典型临床症状，但影像学有一定特点，确诊需要病理和免疫组化检查。治疗原则与其他非小细胞肺癌相似，早期患者是以手术为主的综合治疗模式。但对放化疗不敏感，容易复发和转移，预后不良。随着分子病理学发展，靶向治疗和免疫治疗可能会有广阔的应用前景。 】 【中文关键词：肺肿瘤；肺肉瘤样癌；诊断；治疗；预后】.
Keywords: Diagnosis; Lung neoplasms; Prognosis; Pulmonary sarcomatoid carcinoma; Treatment.